Display options
Share it on

Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019.

Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.

Cancer cell

William G Nelson, Michael C Haffner, Srinivasan Yegnasubramanian

Affiliations

  1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231-1000, USA. [email protected]

PMID: 21741594 PMCID: PMC4479125 DOI: 10.1016/j.ccr.2011.06.019

Abstract

In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously treated by androgen suppression.

Copyright © 2011 Elsevier Inc. All rights reserved.

References

  1. Clin Cancer Res. 2011 Jun 15;17(12):3858-64 - PubMed
  2. Nat Med. 2010 Jul;16(7):793-8 - PubMed
  3. J Natl Compr Canc Netw. 2010 Feb;8(2):211-23 - PubMed
  4. Cancer Res. 2004 Dec 15;64(24):9209-16 - PubMed
  5. J Clin Oncol. 2005 Nov 10;23(32):8253-61 - PubMed
  6. Lancet. 2010 Apr 24;375(9724):1437-46 - PubMed
  7. J Clin Oncol. 2008 Jun 20;26(18):2959-65 - PubMed
  8. Nat Rev Cancer. 2008 Jul;8(7):497-511 - PubMed
  9. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed

Publication Types

Grant support